75 related articles for article (PubMed ID: 19238676)
1. K-ras mutations and cetuximab in colorectal cancer.
De Roock W; Lambrechts D; Tejpar S
N Engl J Med; 2009 Feb; 360(8):834; author reply 835-6. PubMed ID: 19238676
[No Abstract] [Full Text] [Related]
2. K-ras mutations and cetuximab in colorectal cancer.
Codacci-Pisanelli G; Spinelli G; Tomao S
N Engl J Med; 2009 Feb; 360(8):835; author reply 835-6. PubMed ID: 19238679
[No Abstract] [Full Text] [Related]
3. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
[TBL] [Abstract][Full Text] [Related]
4. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
[TBL] [Abstract][Full Text] [Related]
6. K-Ras mutations are changing practice in advanced colorectal cancer.
McNeil C
J Natl Cancer Inst; 2008 Dec; 100(23):1667-9. PubMed ID: 19033564
[No Abstract] [Full Text] [Related]
7. [Genomics arrives to the clinical practices in colorectal cancer].
Jankilevich G
Acta Gastroenterol Latinoam; 2009 Mar; 39(1):81-4. PubMed ID: 19408743
[No Abstract] [Full Text] [Related]
8. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
Rosa R; Melisi D; Damiano V; Bianco R; Garofalo S; Gelardi T; Agrawal S; Di Nicolantonio F; Scarpa A; Bardelli A; Tortora G
Clin Cancer Res; 2011 Oct; 17(20):6531-41. PubMed ID: 21890455
[TBL] [Abstract][Full Text] [Related]
9. Responsiveness to cetuximab without mutations in EGFR.
Tsuchihashi Z; Khambata-Ford S; Hanna N; Jänne PA
N Engl J Med; 2005 Jul; 353(2):208-9. PubMed ID: 16014894
[No Abstract] [Full Text] [Related]
10. KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: Does treatment combination partner matter?
Zhang W; Labonte MJ; Lenz HJ
Ann Oncol; 2011 Feb; 22(2):484-5. PubMed ID: 21278223
[No Abstract] [Full Text] [Related]
11. Colorectal cancer: using blood samples and tumor tissue to detect K-ras mutations.
Li Y; Fu XH; Yuan JQ; Yang ZY; Mao C; Dong XM; Tang JL; Wang SY
Expert Rev Anticancer Ther; 2015 Jun; 15(6):715-25. PubMed ID: 26035720
[TBL] [Abstract][Full Text] [Related]
12. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
Ince WL; Jubb AM; Holden SN; Holmgren EB; Tobin P; Sridhar M; Hurwitz HI; Kabbinavar F; Novotny WF; Hillan KJ; Koeppen H
J Natl Cancer Inst; 2005 Jul; 97(13):981-9. PubMed ID: 15998951
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab for metastatic colorectal cancer.
Bria E; Cuppone F; Di Maio M
N Engl J Med; 2009 Jul; 361(1):95-6; author reply 96-7. PubMed ID: 19579280
[No Abstract] [Full Text] [Related]
14. Cetuximab for metastatic colorectal cancer.
Roila F; Garassino MC; Ballatori E
N Engl J Med; 2009 Jul; 361(1):95; author reply 96-7. PubMed ID: 19579279
[No Abstract] [Full Text] [Related]
15. [Some problems facing the molecular targeting therapy for colorectal cancer].
Xu JM
Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):321-3. PubMed ID: 19799077
[No Abstract] [Full Text] [Related]
16. Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis.
Ma ES; Wong CL; Law FB; Chan WK; Siu D
J Clin Pathol; 2009 Oct; 62(10):886-91. PubMed ID: 19783717
[TBL] [Abstract][Full Text] [Related]
17. [Cetuximab (Erbitux)].
Shimoyama T
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1203-12. PubMed ID: 19620819
[TBL] [Abstract][Full Text] [Related]
18. Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients.
Ruzzo A; Canestrari E; Galluccio N; Santini D; Vincenzi B; Tonini G; Magnani M; Graziano F
Ann Oncol; 2011 Jan; 22(1):234-235. PubMed ID: 20926546
[No Abstract] [Full Text] [Related]
19. Targeted treatments in colorectal cancer: state of the art and future perspectives.
Arnold D; Seufferlein T
Gut; 2010 Jun; 59(6):838-58. PubMed ID: 20551469
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
